NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]
Currently, there are a number of different treatments used to treat recurrent prostate cancer when the primary treatment had radiation has failed. In this situation surgery is considered very difficult and can only be successfully performed by an experienced surgeon, so alternative treatments are often considered. Long-term data about the success of these alternative treatments [...]
Many cancer treatments have the potential to impact your overall quality of life (QoL). Before making any decision to use a treatment it is important to understand what might be the possible impacts of the treatment not only on the disease, but also on your life. Impacts could be positive or they could be negative. [...]
I have talked a lot about our need to take the next step in clinical care, understanding the best sequencing of our drugs. Since we have a number of new drugs to treat advanced prostate cancer we now need to better understand which drugs should be used in which men as well as their proper [...]
New information about a possible bad side effect of hormone therapy (ADT) for men with prostate cancer was just published and it is frightening for men on hormone therapy (ADT). The findings are a result of a joint study conducted by researchers at Penn University Medicine with researchers from Stanford University. What is it that [...]